Glaxo's new HIV combo trounces Gilead's Atripla

GlaxoSmithKline's ambitious effort to make a comeback in the HIV field took another big step forward today. A new HIV combo therapy backed by GSK ($GSK), Pfizer ($PFE) and Shionogi bested the leading treatment for the virus in a head-to-head study, spurring some rave reviews from very bullish analysts. Report